AstraZeneca plc (AZN) Given a GBX 5,150 Price Target at UBS AG
AstraZeneca plc (LON:AZN) received a GBX 5,150 ($67.09) target price from equities researchers at UBS AG in a research note issued to investors on Thursday, www.boersen-zeitung.de reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. UBS AG’s price objective indicates a potential upside of 0.72% from the stock’s previous close.
Other research analysts have also issued reports about the stock. BNP Paribas reissued a “neutral” rating and set a GBX 5,300 ($69.05) target price on shares of AstraZeneca plc in a research note on Monday, April 3rd. HSBC Holdings plc reissued a “reduce” rating and set a GBX 4,200 ($54.72) target price on shares of AstraZeneca plc in a research note on Friday, May 5th. Shore Capital reissued a “sell” rating on shares of AstraZeneca plc in a research note on Wednesday, May 10th. J P Morgan Chase & Co reissued a “neutral” rating on shares of AstraZeneca plc in a research note on Thursday, May 11th. Finally, Berenberg Bank increased their target price on shares of AstraZeneca plc from GBX 5,670 ($73.87) to GBX 5,850 ($76.21) and gave the stock a “buy” rating in a research note on Wednesday, May 17th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of GBX 5,251.80 ($68.42).
AstraZeneca plc (LON:AZN) opened at 4280.50 on Thursday. The firm’s 50-day moving average is GBX 5,211.86 and its 200-day moving average is GBX 4,860.16. The company’s market cap is GBX 54.19 billion. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00.
COPYRIGHT VIOLATION NOTICE: “AstraZeneca plc (AZN) Given a GBX 5,150 Price Target at UBS AG” was first published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/07/27/astrazeneca-plc-azn-given-a-gbx-5150-price-target-at-ubs-ag.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.